Common Ketamine Treatment Myths: A Patient Education Guide

Ketamine discussions often mix accurate facts with broad promises. Patients comparing care in Texas or California deserve enough context to distinguish an approved medication, an off-label use, and an unapproved compounded product. The following questions address misunderstandings that can affect treatment decisions.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

Does an anesthesia approval cover mental health treatment?

No. Approval is specific to a product and its indicated uses. Anesthesia approval does not establish that compounded ketamine treats depression, anxiety, PTSD, or burnout. Ask your clinician to identify the evidence for your diagnosis and the exact formulation being proposed.

Does a prescription remove addiction risk?

No. Ketamine has abuse, misuse, and dependence potential. Share your substance-use history and tell the clinician if you feel urges to take more than prescribed or use it more frequently. A medical setting or a small dose cannot guarantee that these concerns will not arise.

Does dissociation mean treatment is working?

A feeling of detachment, altered perception, or an intense experience does not demonstrate improvement in the condition being treated. Describe distressing or unexpected effects to your clinician. Do not take extra medication to seek a particular experience or assume that lack of dissociation means a dose is inadequate.

Are all nasal sprays interchangeable?

No. An approved esketamine product and a compounded ketamine spray differ in formulation, regulatory review, and required treatment setting. Similar wording on a website does not make them equivalent. Results from one product cannot establish the benefit or risk of another.

Can a convenient treatment replace the rest of my care?

Do not discontinue psychotherapy, prescribed medication, or other care because a service advertises rapid results. Ask how any proposed treatment fits with your existing plan and how your clinicians will coordinate. Depression and PTSD, for example, require diagnosis-specific decisions rather than a single treatment promise.

Can reviews predict my outcome?

Reviews can describe a person’s experience, but they cannot establish your likelihood of benefit, compare medications fairly, or replace safety information. Ask how outcomes are measured, how long patients are followed, and whether people who stop treatment are included in reported results.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: FDA: compounded-drug risks; FDA: compounding risk alerts.